UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

Journal of experimental & clinical cancer research, 2020-05, Vol.39 (1), p.95-95, Article 95

2020

Volltextzugriff (PDF)

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

European journal of cancer (1990), 2020-03, Vol.128, p.17-26

2020

Volltextzugriff (PDF)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Journal for immunotherapy of cancer, 2019-02, Vol.7 (1), p.57-57, Article 57

2019

Volltextzugriff (PDF)

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Journal for immunotherapy of cancer, 2020-11, Vol.8 (2), p.e001361

2020

Volltextzugriff (PDF)

Prognostic and predictive factors in pancreatic cancer

Oncotarget, 2020-03, Vol.11 (10), p.924-941

2020

Volltextzugriff (PDF)

Immunotherapy for colorectal cancer: where are we heading?

Expert opinion on biological therapy, 2017-06, Vol.17 (6), p.709-721

2017

Volltextzugriff (PDF)

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Clinical lung cancer, 2020-11, Vol.21 (6), p.498-508.e2

2020

Volltextzugriff (PDF)

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

Scientific reports, 2015-12, Vol.5 (1), p.18670-18670, Article 18670

2015

Volltextzugriff (PDF)

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

European journal of cancer (1990), 2021-05, Vol.148, p.24-35

2021

Volltextzugriff (PDF)

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib

Oncotarget, 2017-08, Vol.8 (35), p.59986-59990

2017

Volltextzugriff (PDF)

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

Current oncology (Toronto), 2023-02, Vol.30 (2), p.2366-2387

2023

Volltextzugriff (PDF)

Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)

Journal for immunotherapy of cancer, 2024-06, Vol.12 (6), p.e009432

2024

Volltextzugriff (PDF)

Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis

Cancers, 2021-02, Vol.13 (4), p.652

2021

Volltextzugriff (PDF)

Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

Thoracic cancer, 2021-06, Vol.12 (11), p.1791-1792

2021

Volltextzugriff (PDF)

Cabozantinib and apixaban: an hitherto unreported interaction

Experimental hematology & oncology, 2019-09, Vol.8 (1), p.22-2, Article 22

2019

Volltextzugriff (PDF)

Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis

PloS one, 2016-07, Vol.11 (7), p.e0157751-e0157751

2016

Volltextzugriff (PDF)

Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

Journal of experimental & clinical cancer research, 2020-06, Vol.39 (1), p.1-120, Article 120

2020

Volltextzugriff (PDF)

Detection of novel driver mutations in liquid biopsy: case report of a RET-positive lung adenocarcinoma treated with pralsetinib.

Recenti progressi in medicina, 2021-01, Vol.112 (1), p.5e

Russano, Marco

2021

Volltextzugriff (PDF)

Steroid-refractory immune related hepatitis may hide viral re-activation

Future science OA, 2020-10, Vol.6 (9)

2020

Volltextzugriff (PDF)

"Impact of Smoking Cessation Treatment" on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study

Recent patents on anti-cancer drug discovery, 2015-01, Vol.10 (3), p.342-351

2015

Volltextzugriff (PDF)

Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?

Journal of thoracic oncology, 2020-07, Vol.15 (7), p.e105-e106

2020

Volltextzugriff (PDF)

Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study

The oncologist (Dayton, Ohio), 2019-06, Vol.24 (6), p.e327-e337

2019

Volltextzugriff (PDF)

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

European journal of cancer (1990), 2021-01, Vol.142, p.18-28

2021

Volltextzugriff (PDF)

1 – 25 von 97

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(94)
Berichte
(3)

Sprache

Englisch
(94)
Italienisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(55)
Oncology
(48)
Humans
(33)
Immunotherapy
(26)
Male
(19)
Female
(18)
Metastasis
(16)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(13)
Lung Neoplasms - Drug Therapy
(13)
Middle Aged
(13)
Aged
(12)
Immune Checkpoint Inhibitors
(12)
Patients
(12)
Adult
(11)
Cancer
(11)
Lung Cancer
(11)
Melanoma
(11)
Prognosis
(9)
Survival
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Prognostic and predictive factors in pancreatic cancer

Immunotherapy for colorectal cancer: where are we heading?

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study

Change from lung adenocarcinoma to small cell lung cancer as a mechanism of resistance to afatinib

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC)

Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis

Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations

Cabozantinib and apixaban: an hitherto unreported interaction

Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis

Correction to: Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

Large-Scale Profiling of Extracellular Vesicles Identified miR-625-5p as a Novel Biomarker of Immunotherapy Response in Advanced Non-Small-Cell Lung Cancer Patients

Detection of novel driver mutations in liquid biopsy: case report of a RET-positive lung adenocarcinoma treated with pralsetinib.

Steroid-refractory immune related hepatitis may hide viral re-activation

"Impact of Smoking Cessation Treatment" on Lung Function and Response Rate in EGFR Mutated Patients: A Short-Term Cohort Study

Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?

Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Suchergebnisse filtern